ICMR seeks partners to develop antibody against Nipah virus, Pg12

Key Highlights:

• ICMR seeks partners for developing monoclonal antibodies (mAbs) against Nipah virus.
• Nipah virus (NiV) outbreaks in India since 2001 have shown case fatality rates between 40%-75%.
• Monoclonal antibodies (mAbs) can serve as post-exposure prophylaxis (PEP) for high-risk contacts.
• ICMR-National Institute of Virology (ICMR-NIV), Pune has initiated R&D in this direction.

Detailed Insights:

• Nipah virus (NiV) is a zoonotic disease that poses a significant threat in India due to its high fatality rate and the absence of licensed vaccines.
• Monoclonal antibodies (mAbs) are considered the only feasible biomedical countermeasure currently available, and early administration can prevent disease onset.
• This initiative aims to create an indigenous monoclonal antibody (mAb) platform in India to ensure timely access during outbreaks and enhance national preparedness.
• ICMR will provide expert guidance and technical support throughout the R&D process to accelerate product development and commercialization.

Key Concepts Involved:

• Monoclonal Antibodies (mAbs): Laboratory-produced molecules that mimic the body's immune system to fight harmful pathogens.
• Zoonotic Disease: A disease that can be transmitted from animals to humans.
• Post-Exposure Prophylaxis (PEP): Medical treatment started after exposure to a disease to prevent infection.